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Background: Leishmaniasis is a parasitic disease which can
manifest in various clinical forms and the visceral form is highly
fatal if not treated. The drugs available are either highly costly or
have poor efﬁcacy against the parasite. Hence there is a need to ﬁnd
new molecules and compounds for the treatment of this disease.
However, to put the new compounds in clinical trials, their toxic-
ity and immune-modulatory effects must be ascertained to avoid
harmful effects on the host.
Methods & Materials: Putative immunomodulatory activ-
ity of two advanced preclinical anti-kinetoplastid candidates
(KIND0001589 and KIND0001591) was evaluated, using primary
human peripheral blood cells from healthy controls and kala-
azar patients. Amphotericin B was used as standard drug control.
The optimal concentrations of KIND0001589 (0.0134g/mL) and
KIND0001591 (0.03g/mL) was used, to pre-treat the peripheral
blood mononuclear cell, for 14 hours followed by addition of, PMA
(25 ng/mL) and Ionomycin (1g/mL) for 4 hours together with
Brefeldin A (1g/mL). Cell viability was assessed by determining
the frequency of Annexin V/7AAD positive cells in CD3+, CD14+ and
CD19+ leukocyte subpopulations through BD Inﬂux FACS system.
Immunophenotyping was determined in CD3+, CD4+ and CD3+,
CD8+ T cells, CD14+ monocytes and CD19+ B cells. The frequency of
T-cells, monocytes and B-cells expressing IFN, and TNF-, respec-
tively, was determined by the same ﬂow cytometer.
Results: Short termex-vivo immunophenotyping assay showed
KIND001589 induces CD4+TNF- and CD4+IFN including IL-4, IL-
10 and IL-17, in all patients. Where as KIND0001591 induced a
short term immunostimulation of CD8+ T cells. Both KIND000189
and KIND0001591 highly induced CD14+ monocytes (CD14+IFN
andCD14+TNF-) as compared to the standard drug. KIND0001589
does not induce any B cells mediated immuno-stimulation where
as KIND0001591 induced immuno-stimulation in one Patient.
KIND0001589 showed stronger short term immunomodulatory
activity than KIND0001591.
Conclusion: Both the novel compounds (KIND0001589 and
KIND0001589) were found to be safe and potential anti-
kinetoplastids for animal and human trials.
Funding: The study was funded from the European Commu-
nity’s Seventh Framework Program under the grant agreement
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Malaria in Hong Kong: Impact, eradication and
legacy
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Background: This presentation explores how the impact of
malaria and the process of its eradication shaped the development
of Hong Kong, its scientiﬁc and medical expertise and legacy for
preparedness.
Methods & Materials: Primary sources - surviving colonial
medical records, journals, diaries, newspapers and government
reportswere analysed for quantitative and qualitative information.
